Inventaire - your friends and communities are your best library - Inventaire

Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide

author

Hai Fang

published in: Experimental Biology and Medicine

date of publication: 2013-07-24

main subject: endoplasmic reticulum, leukemia

Cites articles 52

Date

Title

Authors

2011-08-17

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Andreas Hochhaus, Richard A. Larson, Ian W. Flinn, Giuseppe Saglio, Hagop Kantarjian, Gianantonio Rosti, Rick E Blakesley, Leif Stenke, Carmino Antônio de Souza, Albert Hoenekopp
2011-09-07

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions

Peter Valent, Oliver Hantschel, Lisa Pleyer, Richard Greil
2011-08-22

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

Jenny Byrne, Tessa Holyoake, Richard Szydlo
2010-11-19

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
2010-04-01

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Francesca Palandri, Gianantonio Rosti, Fausto Castagnetti, Giovanni Martinelli, Gabriele Gugliotta, Michele Baccarani
2010-06-05

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Surapol Issaragrisil, Giuseppe Saglio, Andreas Hochhaus, Richard A. Larson, Hagop Kantarjian, Timothy Hughes, Vernon Louw, Elisabetta Abruzzese, Delphine Rea
2010-05-15

Arsenic trioxide - An old drug rediscovered
2010-02-01

Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment
2010

Effects of nilotinib on regulatory T cells: the dose matters

Markus Rojewski
2009-11-02

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

François Guilhot, Richard A. Larson, Giuseppe Saglio, Andreas Hochhaus, Hagop Kantarjian, Jorge Eduardo Cortes, Michele Baccarani, Fabrizio Pane, Alois Gratwohl, Dietger Niederwieser, Jane F Apperley, Jerald P Radich, European LeukemiaNet
2009-03-12

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

François Guilhot, Andreas Hochhaus, Richard A. Larson, Timothy Hughes
2009-07-01

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients
2009-03-03

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

Quan Chen
2008-06-02

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

Richard Szydlo
2008-06-04

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Mathieu Molimard
2008-01-30

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
2008-10-01

Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia
2008-07-01

Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
2008-12-11

Role of intracellular calcium and S-glutathionylation in cell death induced by a mixture of isothiazolinones in HL60 cells
2008-06-09

Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH.
2007-06-13

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

Munir Pirmohamed, Athina Giannoudis
2007-07-18

Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide

Jun Lu, Arne Holmgren
2007-01

PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways

Paul D Thomas
2007-05-22

The human disease network

Albert-László Barabási, Kwang-Il Goh, Marc Vidal
2007-12-01

S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response

Danyelle M Townsend
2007-04-12

H2S, endoplasmic reticulum stress, and apoptosis of insulin-secreting beta cells
2007-04-25

ER chaperones in mammalian development and human diseases

Amy S Lee
2006-05-18

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

François Guilhot, Richard A. Larson, Giuseppe Saglio, Andreas Hochhaus, Hagop Kantarjian, Jorge Eduardo Cortes, Michele Baccarani, Frederick R. Appelbaum, Alois Gratwohl, Dietger Niederwieser, Jane F Apperley, European LeukemiaNet
2006-08-15

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity

John R. Engen
2006-06-19

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
2006-06-15

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Oliver Ottmann, Andreas Hochhaus, Hagop Kantarjian, Jorge Eduardo Cortes, Susan O'Brien, Francis Giles, Maher Albitar, Kathy Bochinski, Kapil Bhalla, Margaret Dugan, Leila Alland
2006-04-04

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

Deborah L. White, Andrew Zannettino

Article - wd:Q39120817

Welcome to Inventaire

the library of your friends and communities

you are offline